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Background: RA is associated with a 2–3 fold increased risk of both
Hodgkin and non-Hodgkin lymphoma (HL, NHL). The risk of
lymphoma, in particular diffuse large B-cell lymphoma (DLBCL) is
greatest in patients with persistently active RA: those patients that are
also most likely to receive biologics. There has been a concern that
TNF inhibitors (TNFis) could increase the risk of lymphoma via reduced
immunosurveillance. Conversely, TNFis may, by improving disease
control, decrease the lymphoma risk, especially risk of DLBCL. This
abstract describes a EULAR initiative to describe the spectrum of
lymphomas occurring in biologic-naivepatients with RA and those
treated with biologics.
Methods: Patients with RA were included from 11 European biologics
registers in 8 countries and followed prospectively for the occurrence
of first ever lymphoma, confirmed with histology. Patients were
considered to be exposed to a biologic agent after receiving the first
dose and lymphomas were attributed to the most recently received
biologic drug. For the TNFi cohort, prior exposure to biologic drugs
was not permitted. Prior exposure to TNFi was allowed for other
biologic drugs. Frequency of lymphoma subtypes was recorded for
each drug class.
Results: Data for 130 462 patients were available for the analysis
(Sweden, n¼61 527; Denmark, n¼21 454; UK, n¼17 907; Germany,
n¼ 12 581; Portugal, n¼5031; Spain, n¼ 4590; France, n¼ 4512;
Czech Republic, n¼2860): the mean age was 59 years and 74%
female. In total, 520 lymphomas with subtype information were
included in Table 1. Patient-years were available for 493
lymphomas, corresponding to an overall crude incidence rate (IR)
of 8.3 (95% CI 7.6, 9.1). DLBCL was the most frequent subtype
(37% of all lymphomas; Table 1). 9% of lymphomas were HL and 6%
were T cell, with no cases of hepatosplenic T cell lymphoma.
Importantly, the distribution of subtypes was similar across treatment
groups.
Conclusion: This large collaborative analysis of European registries
has successfully collated subtype information on more than 500
lymphomas. There was no evidence of modification of the distribution
of lymphoma subtypes reported in patients following exposure to
biologics. This collaboration facilitates more detailed analyses,
accounting for age, sex, country and specific TNFi, as well as RA-
related factors.
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O07 TABLE 1. Subtypes of lymphoma reported in biologic-naiveand cohorts of patients with RA
All Biologic-naive TNFi Rituximab Tocilizumab Abatacept
Patients in cohort, n 130462 71866 41078 9880 4800 2838
Total follow up time, person-years 592245 322422 226080 30606 7122 6015
Female, % 774 72 77 79 80 78
Age, mean 59 61 55 58 56 57
Total number of lymphomas 520a 288 219a 6 5 2
Lymphoma subtypes, n (% of cohort)
Hodgkin lymphoma 45 (9) 21 (7) 24 (11) 0 0 0
B cell lymphomas 389 (75) 220 (76) 157 (72) 5 (83) 5 (100) 2 (100)
Chronic lymphocytic / small cell 55 (11) 28 (10) 24 (11) 1 (17) 2 (40) 0
B cell HHL lymphoplasmacytic (Waldenstrom macroglobulinaemia) 11 (2) 4 (1) 6 (3) 1 (17) 0 0
Marginal zone 9 (2) 1 (0) 8 (4) 0 0 0
Follicular 67 (13) 33 (11) 32 (15) 1 (17) 0 1 (50)
Mantel cell 5 (1) 5 (2) 0 0 0 0
Diffuse large B cell 194 (37) 113 (39) 75 (34) 2 (33) 3 (60) 1 (50)
Unspecified B cell 48 (9) 36 (13) 12 (5) 0 0 0
T cell lymphomas 32 (6) 17 (6) 14 (6) 1 (17) 0 0
Peripheral T cell 12 (2) 6 (2) 5 (2) 1 (17) 0 0
Angioimmunoblastic 5 (1) 3 (1) 2 (1) 0 0 0
Anaplastic large cell 1 (0) 1 (0) 0 0 0 0
LGL T cell 0 0 0 0 0 0
Pleomorphic T cell 2 (0) 0 2 (1) 0 0 0
Hepatosplenic T cell 0 0 0 0 0 0
Unspecified T cell 12 (2) 7 (2) 5 (2) 0 0 0
Unspecified non-Hodgkin lymphoma/lymphoma 53 (10) 30 (10) 23 (11) 0 0 0
All percentages represent the % of the total number of patients with lymphoma in that cohort with Hodgkin lymphoma, B and T cell lymphomas and unspecified non-
Hodgkin lymphoma or lymphoma (totalling 100%). a27 lymphomas, but no follow-up time, are included from the RATIO registry, France. HHL: heavy-heavy and heavy-light
chanins;LGL: large granular lymphocytic.
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